Passengers queue up to get their temperature checked for COVID-19 symptoms after arriving at a railway platform in Mumbai on Aug. 20, 2021.PUNIT PARANJPE/AFP/Getty Images
India’s drug regulator has granted emergency use approval for Zydus Cadila’s COVID-19 vaccine, the world’s first DNA shot against the coronavirus, in adults and children aged 12 years and above.
The approval gives a boost to India’s vaccination program, which aims to inoculate all eligible adults by December, and will provide the first shot for those under 18, as the country still struggles to contain the virus spread in some states.
The vaccine, ZyCoV-D, uses a section of genetic material from the virus that gives instructions as either DNA or RNA to make the specific protein that the immune system recognizes and responds to.
India to miss end-July COVID-19 vaccination target as Covaxin supply lags
India’s excess deaths during COVID-19 pandemic up to 4.9 million, study shows
Unlike most COVID-19 vaccines, which need two doses or even a single dose, ZyCoV-D is administered in three doses.
The generic drug maker, listed as Cadila Healthcare Ltd., aims to make 100 million to 120 million doses of ZyCoV-D annually and has already begun stockpiling the vaccine.
Zydus Cadila’s vaccine, developed in partnership with the Department of Biotechnology, is the second homegrown shot to get emergency authorization in India after Bharat Biotech’s Covaxin.
The drug maker said in July its COVID-19 vaccine was effective against the new coronavirus mutants, especially the Delta variant, and that the shot is administered using a needle-free applicator, as opposed to traditional syringes.
The regulatory nod makes ZyCoV-D the sixth vaccine authorized for use in the country, where only about 9.18 per cent of the entire population has been fully vaccinated so far, according to Johns Hopkins data.
Zydus Cadila had also submitted data evaluating a two-dose regimen for the shot in July and plans to seek regulatory approval for the same.
The firm had applied for the authorization of ZyCoV-D on July 1, based on an efficacy rate of 66.6 per cent in a late-stage trial of more than 28,000 volunteers nationwide.
Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.